133 related articles for article (PubMed ID: 12966417)
1. Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
Fujita A; Ohkubo T; Hoshino H; Takabatake H; Tagaki S; Sekine K; Abe S
Br J Cancer; 2003 Sep; 89(6):1008-12. PubMed ID: 12966417
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Oncology; 1999; 56(4):301-7. PubMed ID: 10343194
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Fujita A; Ohkubo T; Hoshino H; Takabatake H; Tagaki S; Sekine K
Anticancer Drugs; 2002 Jun; 13(5):505-9. PubMed ID: 12045462
[TBL] [Abstract][Full Text] [Related]
5. Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Oncology; 2000 Aug; 59(2):105-9. PubMed ID: 10971167
[TBL] [Abstract][Full Text] [Related]
6. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.
Cardenal F; Domine M; Massutí B; Carrato A; Felip E; Garrido P; Juan O; Artal A; Barneto I; López-Vivanco G; Balcells M; Rosell R
Lung Cancer; 2003 Feb; 39(2):201-7. PubMed ID: 12581574
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
Oshita F; Noda K; Nishiwaki Y; Fujita A; Kurita Y; Nakabayashi T; Tobise K; Abe S; Suzuki S; Hayashi I; Kawakami Y; Matsuda T; Tsuchiya S; Takahashi S; Tamura T; Saijo N
J Clin Oncol; 1997 Jan; 15(1):304-9. PubMed ID: 8996157
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Scagliotti GV; Ricardi U; Crinó L; Maranzano E; De Marinis F; Morandi MG; Meacci L; Marangolo M; Emiliani E; Rosti G; Figoli F; Bolzicco G; Masiero P; Gentile A; Tonato M
Cancer Chemother Pharmacol; 1996; 38(6):561-5. PubMed ID: 8823499
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Hojo F; Matsumoto T; Ohmatsu H; Goto K; Kodama T; Eguchi K; Shinkai T; Tamura T; Ohe Y; Kunitoh H; Yoshimura K; Saijo N
Br J Cancer; 2003 Mar; 88(6):808-13. PubMed ID: 12644814
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
13. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
[TBL] [Abstract][Full Text] [Related]
14. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Anticancer Drugs; 2000 Nov; 11(10):821-4. PubMed ID: 11142689
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer.
Fujita A; Fukuoka S; Takabatake H; Tagaki S; Sekine K
Oncology; 2000 Nov; 59(4):291-5. PubMed ID: 11096340
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies of irinotecan alone and in combination with cisplatin.
Fukuoka M; Masuda N
Cancer Chemother Pharmacol; 1994; 34 Suppl():S105-11. PubMed ID: 8070018
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer; 1998 Jun; 82(11):2166-72. PubMed ID: 9610696
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.
Fukuda M; Soda H; Fukuda M; Kinoshita A; Nakamura Y; Nagashima S; Takatani H; Tsukamoto K; Kohno S; Oka M
Cancer; 2007 Aug; 110(3):606-13. PubMed ID: 17577234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
